Kalcicur

Calcium, the active ingredient in Kalcicur, is a mineral supplement presented as a sterile intravenous solution for intravenous use. It helps restore calcium levels in patients with acute hypocalcemia and supports bone mineralization and cellular functions. It is used in acute care settings to correct low serum calcium, to stabilize cardiac membranes during hyperkalemia treatment, and to support calcium balance during major surgeries.

GNH USA supplies Kalcicur as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide.

Kalcicur is used intravenously to address conditions related to calcium deficiency or acute disturbances in calcium homeostasis. - Acute hypocalcemia: rapid restoration of serum calcium levels to prevent neuromuscular irritability and cardiac complications. - Calcium supplementation during major surgery: maintains calcium balance when blood loss or transfusion may lower calcium. - Management of hyperkalemia: stabilizes cardiac membranes by counteracting potassium‑induced excitability. - Post‑operative osteoporotic fracture care: provides supplemental calcium to support bone healing when oral intake is limited.

Intravenous calcium can be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Local irritation at the infusion site: pain, redness, or swelling. - Nausea or vomiting: transient gastrointestinal discomfort. - Transient hypotension: mild drop in blood pressure during infusion. - Flushing or warmth sensation: feeling of heat in the face or upper body.

Serious or Rare Side Effects: - Cardiac arrhythmias: abnormal heart rhythms, especially with rapid infusion. - Hypercalcemia: excessively high serum calcium leading to confusion or kidney stones. - Tissue necrosis: severe extravasation causing tissue damage. - Severe allergic reaction: anaphylaxis with rash, bronchospasm, or hypotension.

When administering Kalcicur, several precautions should be observed to ensure patient safety and product integrity. - Verify serum calcium: confirm low calcium levels before infusion. - Infuse slowly: administer over 10‑20 minutes to reduce risk of cardiac events. - Monitor cardiac function: continuous ECG monitoring during and after infusion. - Avoid in severe renal impairment without adjustment: calcium accumulation risk. - Use with caution in patients on digoxin: increased risk of toxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Calcium may interact with several medications, altering their efficacy or safety profile.

Major Interactions (Avoid): - Calcium and bisphosphonates: concurrent use reduces bisphosphonate absorption; separate administration by at least 30 minutes. - Calcium and loop diuretics: may exacerbate hypercalcemia; monitor serum levels closely. - Calcium and digitalis glycosides: increased risk of digitalis toxicity due to calcium‑mediated effects on cardiac conduction.

Moderate Interactions (Monitor Closely): - Calcium and quinidine: may enhance quinidine’s cardiac effects; ECG monitoring recommended. - Calcium and thiazide diuretics: additive hypercalcemic effect; periodic calcium checks advised. - Calcium and iron supplements: reduced absorption of both agents; stagger dosing by at least 2 hours.